Back to MOLNView full pipeline
Phase 2
Development Phase
0
Upcoming Catalysts
0
Historical Events
0
Regulatory Approvals
No Catalysts Found
No catalyst events have been recorded for this drug yet.
Competitive Landscape
0 competitors in Large Cell Neuroendocrine Carcinoma
View Full LandscapeDrug Information
Target Indication
Large Cell Neuroendocrine Carcinoma
Clinical Trial
NCT07278479Last updated: 1/11/2026
Patent & Exclusivity
No patent data available. Pre-approval drugs may not have Orange Book listings.
Drug Science
Mechanism of action & safety profile
Related Pipeline
4D-150 IVT (3E10 vg/eye)Phase 3
Macular Neovascularization Secondary to Age-Related Macular Degeneration
MP0420Phase 3
COVID-19
MP0250 plus BOR+DEXPhase 2
Multiple Myeloma in Relapse
4D-310Phase 2
Fabry Disease
MP0533 (multispecific DARPin CD3 Engager Targeting CD33, CD123 and CD70) monotherapy, Part 1Phase 2
Leukemia
Get Catalyst Alerts
Receive weekly digests of upcoming catalysts